Radiation Oncology Research

Decades of radiation oncology research has transformed the way cancer patients are treated, leading to better outcomes and longer lives.

UMGCCC'S Department of Radiation Oncology is a national leader in radiation oncology therapy research, ranking in the top 10 for federal funding in radiation oncology.

UMGCCC is also one of only four cancer centers in the country to have a Master Research Agreement with Varian Medical Systems, the market leader in the development of medical technology.

Our own physician-scientists are creating new ways to deliver radiation therapy, including breakthroughs like GammaPod and RapidArc. Our team has active research in a number of specialties, including brachytherapy, hyperthermia and neuro-oncology.

For more information on research activities in the Department of Radiation Oncology please call 410-328-2326 or contact:

Gammapod

Gammapod is the first radiation therapy system dedicated specifically to treating early-stage breast cancer.

It delivers a higher dose of radiation to the tumor while also sending less radiation to nearby vital organs, like the heart and lungs.

Doctors and scientists at the University of Maryland invented and developed GammaPod, which the U.S. Food and Drug Administration cleared for use in 2017.

Learn more about GammaPod.

RapidArc

RapidArc delivers high-dose radiation to tumors two to eight times faster than conventional methods.

It allows for fast, accurate treatments in a very precise way. Patients can be in and out of treatment quickly, often in less than 2 minutes, which means less time the patient is exposed to radiation.

RapidArc technology was originally invented by Cedric X. Yu, DSc, Mansfield Professor of Radiation Oncology at the University of Maryland School of Medicine and member of the radiologic physics team in the Department of Radiation Oncology at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.

Learn more about RapidArc.

Hyperthermia

Will need to add text here